PLX Stock Analysis: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.34
0.27 (13.04%)
▲
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 16, 2026
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
6 traders called PLX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: PLX is 10.4% above fair value ($2.12). Market expects 4.0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: PLX is 10.4% above fair value ($2.12). Market expects 4.0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.34, which is considered extended relative to its 30-day fair value range of $1.79 to $2.12. From a valuation perspective, the stock is trading at a premium (Forward PE: 11.8) compared to its historical average (10.5). At these levels, the market is pricing in 4.0% annual earnings growth.
Technical Outlook: Technically, PLX is in a downtrend. The price is approaching resistance at $2.13. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 13.0% recently.
Market Sentiment: PLX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.00 (+431.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLX is in a downtrend. The price is approaching resistance at $2.13. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 13.0% recently.
Market Sentiment: PLX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.00 (+431.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$1.79 -
$2.12
Company Quality Score
68/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
60.5%
Protect Your Profits
PLX is technically overbought (RSI 73). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+10.4% above fair value)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+13.0%)
- BULLISH: Trading 431.4% below Wall St target ($11.00)
- BULLISH: Expecting earnings turnaround to 4.0% growth with -0.6% revenue growth
- WARNING: Recommendation downgraded due to 10.4% overvaluation
Fair Price Analysis
30-Day Fair Range
$1.79 -
$2.12
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$1.97
Resistance Level
$2.13
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
11.83
Wall Street Target
$11.00
(+431.4%)
Revenue Growth (YoY)
-0.6%
Earnings Growth (YoY)
-1.0%
Profit Margin
8.7%
Valuation Premium vs History
+4.0% premium
PE vs Historical
11.8 vs 10.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.0%
(market-implied from PE analysis)
1-Year Target
$2.15
(+4%)
2-Year Target
$2.24
(+8%)
3-Year Target
$2.33
(+13%)
3-Yr Target (if PE normalizes)
(PE: 12→11)
PE COMPRESSION
$2.07
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 600.0%)
$13.17
(+536%)
Base:
(SPY PE: 11.8, Growth: 600.0%)
$6.99
(+238%)
Bear:
(PE: 10.1, Growth: 600.0%)
$5.94
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 25.75 | Current EPS (TTM): $0.08
Bull Case
$4.53
(+94%)
Analyst growth 100.0%, PE expands to 28.3
Base Case
$4.12
(+76%)
Market implied 100.0%, PE stable at 25.8
Bear Case
$1.40
(-40%)
Severe decline -20.0%, PE contracts to 21.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 8:59 AM ET
Data refreshes hourly during market hours. Next update: 9:59 AM
Data refreshes hourly during market hours. Next update: 9:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
Advanced PLX Option Strategies
Professional options setups generated by AI based on today's PLX price and gamma walls.
